Pharmaceutical Acquisition Increases UBI-Asia’s Presence

May 21, 2001 — HSINCHU — United Biomedical Inc.’s Asian Operation Center (UBI-Asia) has acquired Glaxo SmithKline’s Hsinchu pharmaceutical manufacturing plant.

According to a report in the China Post, the deal makes UBI-Asia the leading producer of pharmaceuticals in Taiwan and puts the company at the front of the pack of companies expanding their East Asia presence.

The facility includes about 200,000 square feet of pharmaceutical manufacturing facilities and will be operated in accordance with international guidelines for pharmaceutical production.

Under the deal, UBI-Asia will manufacture pharmaceutical products to meet the demands of existing GSK consumers in the region. UBI also plans to export products made at its new facility to overseas markets, particularly the East Asia region. Officials say the deal with Glaxo SmithKline will also serve as a springboard for the UBI’s parent company expansion into the area.

UBI-Asia currently operates one pharmaceutical manufacturing plant in Hsinchu. That plant was acquired from F. Hoffman La-Roche Ltd. in 1999 through a similar agreement.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.